X4 Pharmaceuticals, Inc.
XFORHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, X4 Pharmaceuticals, Inc. (XFOR) is listed under Biotechnology. Valued at $321.2M, XFOR is a small-cap name in its sector. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Market Cap
$321.2M
Beta
0.46
P/E (TTM)
162.00
P/E (Fwd)
-4.22
EPS (TTM)
$0.02
EPS (Fwd)
$-0.77
ROE
-113.1%
ROA
-28.1%
Cash
$208.0M
Total Debt
$77.2M
Free CF
-$53.3M
52W Change
-13.4%
Annual Financials
Cash vs Debt
Where XFOR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, XFOR finished 29.31% below its 150-day moving average ($3.89) and 28.20% below its 200-day moving average ($3.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XFOR overbought or oversold?
At the October 20, 2026 close, XFOR's RSI(14) was 44.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $208.0M in cash comfortably exceeding the $77.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$53.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -113.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, X4 Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence X4 Pharmaceuticals, Inc.'s trajectory.